TY - JOUR
T1 - T-cell therapy in the treatment of post-transplant lymphoproliferative disease
AU - Bollard, Catherine M.
AU - Rooney, Cliona M.
AU - Heslop, Helen E.
N1 - Funding Information:
This work was supported by grants P01CA094237, P50CA126752 and U54HL08100 from the NIH and a SCOR award from the Leukemia and Lymphoma Society.
PY - 2012/9
Y1 - 2012/9
N2 - Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.
AB - Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.
UR - http://www.scopus.com/inward/record.url?scp=84865688046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865688046&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2012.111
DO - 10.1038/nrclinonc.2012.111
M3 - Review article
C2 - 22801669
AN - SCOPUS:84865688046
SN - 1759-4774
VL - 9
SP - 510
EP - 519
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 9
ER -